The Wound Center of Niagara at Niagara Falls Memorial Medical Center is participating in a national multi-center study of Aurix, a potential therapy for treating chronic, non-healing wounds.
The Centers for Medicare and Medicaid Services recently approved amended protocols that will allow the federal agency to reimburse for Nuo Therapeutics' Aurix when health care providers agree to collect eligible Medicare patients' treatment data for inclusion in the the randomized, controlled trial database.
Aurix is a gel derived from a patient's own blood platelets and plasma for treatment of such medical issues as diabetic foot ulcers, venous leg ulcers and pressure ulcers. Once topically applied, it stimulates the formation of new tissue to fill in wound defects and reduce wound volume. The therapy will be compared with standard care for these types of wounds.
To learn more about the study, call 1-866-298-6633.